Autosomal dominant polycystic kidney disease in children

Curr Opin Pediatr. 2015 Apr;27(2):193-200. doi: 10.1097/MOP.0000000000000195.

Abstract

Purpose of review: Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary renal disease, affecting one in 500 individuals. The cardinal manifestation of ADPKD is progressive cystic dilatation of renal tubules with kidney enlargement and progression to end-stage renal disease in approximately half of cases by 60 years of age. Although previously considered a condition of adults, it is clear that children and young adults are subject to the complications of ADPKD.

Recent findings: It has been increasingly recognized that interventions early in life are necessary in order to confer the best long-term outcome in this common condition. Therefore, it is imperative for pediatricians to recognize the manifestations and complications of this disease. Until recently ADPKD management focused on general principles of chronic kidney disease. However, several recent clinical trials in children and adults with ADPKD have focused on disease-specific therapies.

Summary: This review will highlight the clinical manifestations, diagnosis, and appropriate management of ADPKD in childhood and will review recent relevant clinical trials in children and adults with this condition.

Publication types

  • Review

MeSH terms

  • Blood Pressure
  • Child
  • Child, Preschool
  • Diet, Sodium-Restricted
  • Disease Progression
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Kidney / diagnostic imaging
  • Kidney / pathology*
  • Kidney Failure, Chronic / etiology
  • Kidney Failure, Chronic / physiopathology*
  • Kidney Failure, Chronic / therapy
  • Kidney Transplantation
  • Polycystic Kidney, Autosomal Dominant / complications
  • Polycystic Kidney, Autosomal Dominant / diagnostic imaging
  • Polycystic Kidney, Autosomal Dominant / physiopathology*
  • Polycystic Kidney, Autosomal Dominant / therapy
  • Pravastatin / therapeutic use*
  • Prognosis
  • Renal Dialysis
  • Ultrasonography

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Pravastatin